down arrow

Becton, Dickinson & Co.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0758871091
USD
193.76
0.19 (0.1%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

192.15194.06

52 Week

162.50251.99
Valuation
Technical
Day's Volume

CASH

391.74 k

Shareholding (Mar 2025)

FII

26.87%

Held by 516 FIIs

DII

36.14%

Held by 69 DIIs

Promoter

0.06%

How big is Becton, Dickinson & Co.?

22-Jun-2025

As of Jun 18, Becton, Dickinson & Co. has a market capitalization of $62.33 billion, with recent net sales of $20.87 billion and a net profit of $1.52 billion. As of Sep 24, the company reported total assets of $57.29 billion and shareholder's funds of $25.89 billion.

Market Cap: As of Jun 18, Becton, Dickinson & Co. has a market capitalization of 62,329.13 million, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Becton, Dickinson & Co. reported net sales of 20,867.00 million and a net profit of 1,519.00 million.<BR><BR>Balance Sheet Snapshot: As of Sep 24, the company reported shareholder's funds of 25,890.00 million and total assets of 57,286.00 million.

Read More

What does Becton, Dickinson & Co. do?

22-Jun-2025

Becton, Dickinson and Company (BD) is a global medical technology firm that develops and sells medical supplies, devices, and diagnostic products. As of March 2025, it reported net sales of $5.27 billion and a market cap of approximately $62.33 billion.

Overview:<BR>Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture, and sale of a range of medical supplies, devices, laboratory equipment, and diagnostic products, operating in the Pharmaceuticals & Biotechnology industry with a large-cap market classification.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 5,272 Million (Quarterly Results - Mar 2025)<BR>Most recent Net Profit: 308 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 62,329.13 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 33.00<BR>Dividend Yield: 1.89%<BR>Debt Equity: 0.73<BR>Return on Equity: 7.64%<BR>Price to Book: 2.47<BR><BR>Contact Details:<BR>Address: 1 Becton Dr, FRANKLIN LAKES NJ: 07417-1815<BR>Tel: 1 201 8476800<BR>Website: http://www.bd.com/

Read More

Who are in the management team of Becton, Dickinson & Co.?

22-Jun-2025

As of March 2022, Becton, Dickinson & Co.'s management team includes Executive Chairman Vincent Forlenza and CEO Thomas Polen, along with several independent directors: Marshall Larsen, Catherine Burzik, R. Andrew Eckert, Claire Fraser, and Jeffrey Henderson.

As of March 2022, the management team of Becton, Dickinson & Co. includes the following individuals:<BR><BR>- Mr. Vincent Forlenza, who serves as the Executive Chairman of the Board.<BR>- Mr. Thomas Polen, who holds the positions of President, Chief Executive Officer, Chief Operating Officer, and Director.<BR>- Mr. Marshall Larsen, who is the Lead Independent Director.<BR>- Ms. Catherine Burzik, who is an Independent Director.<BR>- Mr. R. Andrew Eckert, who is also an Independent Director.<BR>- Ms. Claire Fraser, who serves as an Independent Director.<BR>- Mr. Jeffrey Henderson, who is an Independent Director.<BR><BR>In summary, the management team comprises key executives and independent directors, with Mr. Thomas Polen as the CEO and Mr. Vincent Forlenza as the Executive Chairman.

Read More

Is Becton, Dickinson & Co. overvalued or undervalued?

05-Nov-2025

As of October 31, 2025, Becton, Dickinson & Co. is considered overvalued with a valuation grade of expensive, reflected in its high P/E ratio of 33 and underperformance of -21.08% year-to-date compared to the S&P 500's 16.30% return.

As of 31 October 2025, the valuation grade for Becton, Dickinson & Co. has moved from very expensive to expensive. This suggests that the company is currently overvalued. Key valuation ratios include a P/E ratio of 33, an EV to EBITDA of 16.57, and a PEG ratio of 2.36, all indicating a premium valuation relative to its peers. For comparison, Abbott Laboratories has a P/E of 18.36 and Thermo Fisher Scientific, Inc. has an EV to EBITDA of 21.65, highlighting that Becton, Dickinson & Co. is trading at a higher valuation than these competitors.<BR><BR>In terms of recent performance, Becton, Dickinson & Co. has underperformed significantly against the S&P 500, with a year-to-date return of -21.08% compared to the S&P 500's 16.30%. This further reinforces the notion that the stock may be overvalued in the current market environment.

Read More

Is Becton, Dickinson & Co. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Becton, Dickinson & Co. is in a bearish trend, indicated by negative signals from MACD, Bollinger Bands, and moving averages, with a year-to-date return of -21.08% compared to the S&P 500's 16.30%.

As of 31 October 2025, the technical trend for Becton, Dickinson & Co. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators: both the weekly and monthly MACD are bearish, Bollinger Bands are bearish across both time frames, and daily moving averages also indicate a bearish trend. The KST and Dow Theory show mildly bearish signals on the weekly but bearish on the monthly. <BR><BR>In terms of performance, the stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -21.08% compared to the S&P 500's 16.30%, and a one-year return of -23.89% versus 19.89% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate 5.16% of over the last 5 years

 
2

Negative results in Jun 25

3

With ROCE of 6.24%, it has a expensive valuation with a 1.88 Enterprise value to Capital Employed

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 70,270 Million (Large Cap)

stock-summary
P/E

33.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.53%

stock-summary
Debt Equity

0.73

stock-summary
Return on Equity

7.79%

stock-summary
Price to Book

2.76

Revenue and Profits:
Net Sales:
5,509 Million
(Quarterly Results - Jun 2025)
Net Profit:
574 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.31%
0%
1.31%
6 Months
13.35%
0%
13.35%
1 Year
-12.5%
0%
-12.5%
2 Years
-18.44%
0%
-18.44%
3 Years
-23.23%
0%
-23.23%
4 Years
-18.59%
0%
-18.59%
5 Years
-18.13%
0%
-18.13%

Becton, Dickinson & Co. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Becton, Dickinson & Co. Experiences Valuation Adjustment Amidst Competitive Market Landscape

Becton, Dickinson & Co. Experiences Valuation Adjustment Amidst Competitive Market Landscape

Becton, Dickinson & Co. has recently adjusted its valuation, with its current price at $177.84. Over the past year, the company has experienced a decline, contrasting with the S&P 500's performance. Key metrics include a P/E ratio of 33 and a dividend yield of 1.81%, indicating competitive positioning within the sector.

Read More
Becton, Dickinson & Co. Hits New 52-Week Low at $162.50

Becton, Dickinson & Co. Hits New 52-Week Low at $162.50

Becton, Dickinson & Co. has reached a new 52-week low, reflecting a notable decline over the past year. The company, with a market capitalization of USD 70.27 billion and a P/E ratio of 33.00, faces challenges in long-term growth despite a commitment to shareholder returns through dividends.

Read More

Is Becton, Dickinson & Co. technically bullish or bearish?

As of 31 October 2025, the technical trend for Becton, Dickinson & Co. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators: both the weekly and monthly MACD are bearish, Bollinger Bands are bearish across both time frames, and daily moving averages also indicate a bearish trend. The KST and Dow Theory show mildly bearish signals on the weekly but bearish on the monthly. In terms of performance, the stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -21.08% compared to the S&P 500's 16.30%, and a one-year return of -23.89% versus 19.89% for the index....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
4.80%
EBIT Growth (5y)
5.16%
EBIT to Interest (avg)
5.60
Debt to EBITDA (avg)
3.26
Net Debt to Equity (avg)
0.73
Sales to Capital Employed (avg)
0.46
Tax Ratio
11.22%
Dividend Payout Ratio
64.86%
Pledged Shares
0
Institutional Holding
96.61%
ROCE (avg)
6.58%
ROE (avg)
8.05%
Valuation key factors
Factor
Value
P/E Ratio
33
Industry P/E
Price to Book Value
2.52
EV to EBIT
30.10
EV to EBITDA
16.57
EV to Capital Employed
1.88
EV to Sales
3.94
PEG Ratio
2.36
Dividend Yield
1.81%
ROCE (Latest)
6.24%
ROE (Latest)
7.64%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 191 Schemes (36.78%)

Foreign Institutions

Held by 516 Foreign Institutions (26.87%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 4.50% vs 2.01% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 86.36% vs 1.65% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,509.00",
          "val2": "5,272.00",
          "chgp": "4.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,628.00",
          "val2": "1,255.00",
          "chgp": "29.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "152.00",
          "val2": "151.00",
          "chgp": "0.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-97.00",
          "val2": "-90.00",
          "chgp": "-7.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "574.00",
          "val2": "308.00",
          "chgp": "86.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "183.30%",
          "val2": "122.70%",
          "chgp": "6.06%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is 4.16% vs 2.66% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is 11.44% vs -6.42% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "20,178.00",
          "val2": "19,372.00",
          "chgp": "4.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5,231.00",
          "val2": "4,357.00",
          "chgp": "20.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "528.00",
          "val2": "452.00",
          "chgp": "16.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-676.00",
          "val2": "-339.00",
          "chgp": "-99.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,705.00",
          "val2": "1,530.00",
          "chgp": "11.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "153.00%",
          "val2": "113.40%",
          "chgp": "3.96%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
5,509.00
5,272.00
4.50%
Operating Profit (PBDIT) excl Other Income
1,628.00
1,255.00
29.72%
Interest
152.00
151.00
0.66%
Exceptional Items
-97.00
-90.00
-7.78%
Consolidate Net Profit
574.00
308.00
86.36%
Operating Profit Margin (Excl OI)
183.30%
122.70%
6.06%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 4.50% vs 2.01% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 86.36% vs 1.65% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
20,178.00
19,372.00
4.16%
Operating Profit (PBDIT) excl Other Income
5,231.00
4,357.00
20.06%
Interest
528.00
452.00
16.81%
Exceptional Items
-676.00
-339.00
-99.41%
Consolidate Net Profit
1,705.00
1,530.00
11.44%
Operating Profit Margin (Excl OI)
153.00%
113.40%
3.96%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Sep 2024 is 4.16% vs 2.66% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2024 is 11.44% vs -6.42% in Sep 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Becton, Dickinson & Co. stock-summary
stock-summary
Becton, Dickinson & Co.
Pharmaceuticals & Biotechnology
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.
Company Coordinates stock-summary
Company Details
1 Becton Dr , FRANKLIN LAKES NJ : 07417-1815
stock-summary
Tel: 1 201 8476800
stock-summary
http://www.bd.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."